

Short Bio

Franck Perez is Research Director at CNRS and Chairman of the "Cell Biology and Cancer" Unit of the Institut Curie in Paris. His group is studying intracellular trafficking with an important focus on the development of new methods and tools for Cell Biology studies. For example, he developed at the Institut Curie the use of automated cellular screening and co-founded a High Content screening platform (BioPhenics, directed by Elaine del Nery). In addition, his group created a novel trafficking assay and have strongly invested on the development of recombinant antibodies for cell biology. Notably, with Sandrine Moutel, he developed a novel antibody library based on a humanized nanobody scaffold and created a therapeutic antibody platform to exploit and share these technologies.

Prior to being recruited by CNRS, F. Perez was Maître-Assistant at the University of Geneva in Switzerland (1996-1999), in the laboratory of Prof. T. E Kreis where he worked on microtubule dynamics and intracellular trafficking. F. Perez received his PhD. in 1996 for his work in the laboratory of A. Prochiantz at the Ecole Normale Supérieure (Paris, France) on the regulation of neuroendocrine secretion and on the development of cell internalization peptides. Before his PhD., F. Perez graduated in Cell biology and Genetics at the University Paris VII.

F. Perez is an EMBO member, author of about hundred and fifty articles and over twelve patents. He is the co-founder of four biotech companies (Emglev therapeutics [now Valour Bio], Honing Biosciences, The Twinkle Factory and Mnemo therapeutics).